{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:15Z","timestamp":1792603035922,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allergic rhinitis (AR) is the most common undiagnosed chronic condition in children. Moderate\/severe AR symptoms significantly impair quality of life, and cause sleep disruption, absenteeism and decreased productivity. Additionally, untreated AR predisposes children to asthma and other chronic conditions. Although intranasal corticosteroids are the most effective pharmacologic treatment for AR, oral antihistamines are often preferred. First-generation antihistamines may be chosen to relieve AR symptoms as they are inexpensive and widely available; however, they cause sedative and cardiovascular negative effects due to poor receptor selectivity. Therefore, second-generation antihistamines were developed to reduce adverse effects while retaining efficacy. There are fewer clinical trials in children than adults, therefore, efficacy and safety data is limited, particularly in children under 6\u00a0years, highlighting the need to generate these data in young children with AR. Fexofenadine, a highly selective second-generation antihistamine, effectively alleviates symptoms of AR, is non-sedating due to decreased blood\u2013brain barrier permeability, and is devoid of cardiovascular side effects. Importantly, fexofenadine relieves the ocular symptoms of allergic conjunctivitis, which occur concomitantly with AR, improving quality of life. Overall, fexofenadine displays a favorable safety profile and results in greater treatment satisfaction in children compared with other second-generation antihistamines. This review aimed to evaluate and compare the safety and efficacy of fexofenadine with other available first- and second-generation antihistamines in children with AR.<\/jats:p>","DOI":"10.1186\/s13223-021-00614-6","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:04:57Z","timestamp":1635847497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis"],"prefix":"10.1186","volume":"17","author":[{"given":"Eli O.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Augusto","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Van Bever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-7612","authenticated-orcid":false,"given":"Luiz","family":"Lucio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"12","key":"614_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2165\/00002018-200427120-00005","volume":"27","author":"CE Baena-Cagnani","year":"2004","unstructured":"Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf. 2004;27(12):883\u201398. https:\/\/doi.org\/10.2165\/00002018-200427120-00005.","journal-title":"Drug Saf"},{"issue":"12","key":"614_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1185\/030079904x13266","volume":"20","author":"MS Blaiss","year":"2004","unstructured":"Blaiss MS, Rhinitis A, in Schoolchildren Consensus G. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin. 2004;20(12):1937\u201352. https:\/\/doi.org\/10.1185\/030079904x13266.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 2","key":"614_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13223-018-0280-7","volume":"14","author":"P Small","year":"2018","unstructured":"Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma. Clin Immunol. 2018;14(Suppl 2):51. https:\/\/doi.org\/10.1186\/s13223-018-0280-7.","journal-title":"Clin Immunol"},{"issue":"Suppl 86","key":"614_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","volume":"63","author":"J Bousquet","year":"2008","unstructured":"Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8\u2013160. https:\/\/doi.org\/10.1111\/j.1398-9995.2007.01620.x.","journal-title":"Allergy"},{"issue":"4","key":"614_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","volume":"146","author":"MS Dykewicz","year":"2020","unstructured":"Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721\u201367. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"614_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5415\/apallergy.2012.2.2.93","volume":"2","author":"E Mir","year":"2012","unstructured":"Mir E, Panjabi C, Shah A. Impact of allergic rhinitis in school going children. Asia Pac Allergy. 2012;2(2):93\u2013100. https:\/\/doi.org\/10.5415\/apallergy.2012.2.2.93.","journal-title":"Asia Pac Allergy"},{"key":"614_CR7","doi-asserted-by":"publisher","unstructured":"Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. 2017 BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 47(7):856\u201389. doi: https:\/\/doi.org\/10.1111\/cea.12953.","DOI":"10.1111\/cea.12953"},{"issue":"6","key":"614_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.smj.0000221631.98056.87","volume":"99","author":"DL Spangler","year":"2006","unstructured":"Spangler DL, Brunton S. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J. 2006;99(6):593\u20139. https:\/\/doi.org\/10.1097\/01.smj.0000221631.98056.87.","journal-title":"South Med J"},{"key":"614_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/TCRM.S105189","volume":"12","author":"XY Wang","year":"2016","unstructured":"Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, de Wang Y. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016;12:585\u201397. https:\/\/doi.org\/10.2147\/TCRM.S105189.","journal-title":"Ther Clin Risk Manag"},{"key":"614_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20010213","volume":"20","author":"H Kawauchi","year":"2019","unstructured":"Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20:1. https:\/\/doi.org\/10.3390\/ijms20010213.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"614_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/00002018-200124020-00003","volume":"24","author":"AP Ten Eick","year":"2001","unstructured":"Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf. 2001;24(2):119\u201347. https:\/\/doi.org\/10.2165\/00002018-200124020-00003.","journal-title":"Drug Saf"},{"issue":"1","key":"614_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000321896","volume":"156","author":"E Compalati","year":"2011","unstructured":"Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gomez RM, et al. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1\u201315. https:\/\/doi.org\/10.1159\/000321896.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"614_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1081-1206(10)60385-7","volume":"99","author":"FC Hampel","year":"2007","unstructured":"Hampel FC, Kittner B, van Bavel JH. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol. 2007;99(6):549\u201354. https:\/\/doi.org\/10.1016\/S1081-1206(10)60385-7.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"614_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1185\/030079906X112660","volume":"22","author":"J Boyle","year":"2006","unstructured":"Boyle J, Eriksson M, Stanley N, Fujita T, Kumagi Y. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr Med Res Opin. 2006;22(7):1343\u201351. https:\/\/doi.org\/10.1185\/030079906X112660.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"614_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1067\/mai.2003.1384","volume":"111","author":"U Wahn","year":"2003","unstructured":"Wahn U, Meltzer EO, Finn AF Jr, Kowalski ML, Decosta P, Hedlin G, et al. Fexofenadine is efficacious and safe in children (aged 6\u201311 years) with seasonal allergic rhinitis. J Allergy Clin Immunol. 2003;111(4):763\u20139. https:\/\/doi.org\/10.1067\/mai.2003.1384.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"614_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10928-014-9356-2","volume":"41","author":"JM Martinez","year":"2014","unstructured":"Martinez JM, Khier S, Morita S, Rauch C, Fabre D. Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients. J Pharmacokinet Pharmacodyn. 2014;41(2):187\u201395. https:\/\/doi.org\/10.1007\/s10928-014-9356-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6 Pt 1","key":"614_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/s0091-6749(96)80192-8","volume":"98","author":"FE Simons","year":"1996","unstructured":"Simons FE, Bergman JN, Watson WT, Simons KJ. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol. 1996;98(6 Pt 1):1062\u20134. https:\/\/doi.org\/10.1016\/s0091-6749(96)80192-8.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"614_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2500\/aap.2008.29.3136","volume":"29","author":"N Segall","year":"2008","unstructured":"Segall N, Grubbe RE, Levy AL, Maloney MJ, Nayak AS, Kittner B, et al. Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. Allergy Asthma Proc. 2008;29(4):380\u20135. https:\/\/doi.org\/10.2500\/aap.2008.29.3136.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"614_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1081-1206(10)60553-4","volume":"99","author":"H Milgrom","year":"2007","unstructured":"Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol. 2007;99(4):358\u201363. https:\/\/doi.org\/10.1016\/S1081-1206(10)60553-4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"614_CR20","first-page":"169","volume":"23","author":"J Ngamphaiboon","year":"2005","unstructured":"Ngamphaiboon J, Direkwattanachai C, Visitsunthorn N, Vangveeravong M, Tiensuwan M. The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac J Allergy Immunol. 2005;23(4):169\u201374.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"614_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1399-3038.2004.00167.x","volume":"15","author":"EO Meltzer","year":"2004","unstructured":"Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis\u2013a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15(3):253\u201360. https:\/\/doi.org\/10.1111\/j.1399-3038.2004.00167.x.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"614_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1081-1206(10)62317-4","volume":"87","author":"DF Graft","year":"2001","unstructured":"Graft DF, Bernstein DI, Goldsobel A, Meltzer EO, Portnoy J, Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87(1):22\u20136. https:\/\/doi.org\/10.1016\/S1081-1206(10)62317-4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"614_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jaip.2016.10.010","volume":"5","author":"EO Meltzer","year":"2017","unstructured":"Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017;5(3):779\u201389. https:\/\/doi.org\/10.1016\/j.jaip.2016.10.010.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"4","key":"614_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00044011-199918040-00008","volume":"18","author":"RA Nathan","year":"1999","unstructured":"Nathan RA, Mason J, Bernstein DI, Howland WC, Kaiser HB, Meltzer EO, et al. Long-term tolerability of fexofenadine in healthy volunteers. Clin Drug Investig. 1999;18(4):317\u201328. https:\/\/doi.org\/10.2165\/00044011-199918040-00008.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"614_CR25","first-page":"235","volume":"5","author":"LA Tanner","year":"1999","unstructured":"Tanner LA. Effect of fexofenadine HCL on qualtiy of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care. 1999;5(4):235\u201347.","journal-title":"Am J Manag Care"},{"issue":"10","key":"614_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1517\/14656566.9.10.1655","volume":"9","author":"HW Lee","year":"2008","unstructured":"Lee HW, Lee HW, Park DJ, Moon SO, Ahn JH, Kim MJ, et al. The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers. Expert Opin Pharmacother. 2008;9(10):1655\u201365. https:\/\/doi.org\/10.1517\/14656566.9.10.1655.","journal-title":"Expert Opin Pharmacother"},{"issue":"4 Suppl","key":"614_CR27","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/s0091-6749(03)01879-7","volume":"112","author":"SG Meeves","year":"2003","unstructured":"Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112(4 Suppl):S69-77. https:\/\/doi.org\/10.1016\/s0091-6749(03)01879-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"614_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2165\/00003495-200059020-00020","volume":"59","author":"K Simpson","year":"2000","unstructured":"Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000;59(2):301\u201321. https:\/\/doi.org\/10.2165\/00003495-200059020-00020.","journal-title":"Drugs"},{"issue":"Suppl 3","key":"614_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1046\/j.1365-2222.1999.0290s3212.x","volume":"29","author":"C Pratt","year":"1999","unstructured":"Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(Suppl 3):212\u20136. https:\/\/doi.org\/10.1046\/j.1365-2222.1999.0290s3212.x.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"614_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1046\/j.1365-2133.2000.03576.x","volume":"142","author":"S Dhar","year":"2000","unstructured":"Dhar S, Hazra PK, Malakar S, Mistri G. Fexofenadine-induced QT prolongation: a myth or fact? Br J Dermatol. 2000;142(6):1260\u20131. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03576.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"614_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bjorl.2017.01.008","volume":"84","author":"J Loekmanwidjaja","year":"2018","unstructured":"Loekmanwidjaja J, Carneiro ACF, Nishinaka MLT, Munhoes DA, Benezoli G, Wandalsen GF, et al. Sleep disorders in children with moderate to severe persistent allergic rhinitis. Braz J Otorhinolaryngol. 2018;84(2):178\u201384. https:\/\/doi.org\/10.1016\/j.bjorl.2017.01.008.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"Suppl 1","key":"614_CR32","first-page":"32","volume":"19","author":"I Jauregui","year":"2009","unstructured":"Jauregui I, Mullol J, Davila I, Ferrer M, Bartra J, del Cuvillo A, et al. Allergic rhinitis and school performance. J Investig Allergol Clin Immunol. 2009;19(Suppl 1):32\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"614_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00063030-200115070-00004","volume":"15","author":"SP Galant","year":"2001","unstructured":"Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? BioDrugs. 2001;15(7):453\u201363. https:\/\/doi.org\/10.2165\/00063030-200115070-00004.","journal-title":"BioDrugs"},{"issue":"2","key":"614_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/1817-1737.62467","volume":"5","author":"D Price","year":"2010","unstructured":"Price D. Asthma and allergic rhinitis: linked in treatment and outcomes. Ann Thorac Med. 2010;5(2):63\u20134. https:\/\/doi.org\/10.4103\/1817-1737.62467.","journal-title":"Ann Thorac Med"},{"issue":"4","key":"614_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00148581-200406040-00003","volume":"6","author":"WE Berger","year":"2004","unstructured":"Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs. 2004;6(4):233\u201350. https:\/\/doi.org\/10.2165\/00148581-200406040-00003.","journal-title":"Paediatr Drugs"},{"issue":"8","key":"614_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1542\/pir.31-8-320.(quiz5)","volume":"31","author":"KA Gargiulo","year":"2010","unstructured":"Gargiulo KA, Spector ND. Stuffy nose. Pediatr Rev. 2010;31(8):320\u20134. https:\/\/doi.org\/10.1542\/pir.31-8-320.(quiz5).","journal-title":"Pediatr Rev."},{"issue":"6","key":"614_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5114\/pdia.2016.63942","volume":"33","author":"P Kuna","year":"2016","unstructured":"Kuna P, Jurkiewicz D, Czarnecka-Operacz MM, Pawliczak R, Woron J, Moniuszko M, et al. The role and choice criteria of antihistamines in allergy management - expert opinion. Postepy Dermatol Alergol. 2016;33(6):397\u2013410. https:\/\/doi.org\/10.5114\/pdia.2016.63942.","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"614_CR38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","volume":"140","author":"JL Brozek","year":"2017","unstructured":"Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2017.03.050.","journal-title":"J Allergy Clin Immunol"},{"key":"614_CR39","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","volume":"9","author":"EB Thangam","year":"2018","unstructured":"Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. The Role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873. https:\/\/doi.org\/10.3389\/fimmu.2018.01873.","journal-title":"Front Immunol"},{"issue":"2","key":"614_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1517\/14656566.9.2.329","volume":"9","author":"LE Mansfield","year":"2008","unstructured":"Mansfield LE. Fexofenadine in pediatrics: oral tablet and suspension formulations. Expert Opin Pharmacother. 2008;9(2):329\u201337. https:\/\/doi.org\/10.1517\/14656566.9.2.329.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"614_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/0019-5154.110832","volume":"58","author":"MK Church","year":"2013","unstructured":"Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219\u201324. https:\/\/doi.org\/10.4103\/0019-5154.110832.","journal-title":"Indian J Dermatol"},{"issue":"12","key":"614_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114336","volume":"9","author":"T Isomura","year":"2014","unstructured":"Isomura T, Kono T, Hindmarch I, Kikuchi N, Murakami A, Inuzuka K, et al. Central nervous system effects of the second-generation antihistamines marketed in Japan\u2013review of inter-drug differences using the proportional impairment ratio (PIR). PLoS ONE. 2014;9(12): e114336. https:\/\/doi.org\/10.1371\/journal.pone.0114336.","journal-title":"PLoS ONE"},{"issue":"2","key":"614_CR43","first-page":"145","volume":"74","author":"EA Bower","year":"2003","unstructured":"Bower EA, Moore JL, Moss M, Selby KA, Austin M, Meeves S. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med. 2003;74(2):145\u201352.","journal-title":"Aviat Space Environ Med"},{"issue":"1","key":"614_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40360-019-0363-1","volume":"20","author":"CZ Huang","year":"2019","unstructured":"Huang CZ, Jiang ZH, Wang J, Luo Y, Peng H. Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):72. https:\/\/doi.org\/10.1186\/s40360-019-0363-1.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"614_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/archdischild-2013-304446","volume":"100","author":"R Fitzsimons","year":"2015","unstructured":"Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122\u201331. https:\/\/doi.org\/10.1136\/archdischild-2013-304446.","journal-title":"Arch Dis Child Educ Pract Ed."},{"issue":"5","key":"614_CR46","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2147\/tcrm.s3229","volume":"4","author":"F Horak","year":"2008","unstructured":"Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008;4(5):1009\u201322. https:\/\/doi.org\/10.2147\/tcrm.s3229.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"614_CR47","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/j.1365-2222.2009.03257.x","volume":"39","author":"P Kuna","year":"2009","unstructured":"Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338\u201347. https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03257.x.","journal-title":"Clin Exp Allergy"},{"key":"614_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/JAA.S164632","volume":"11","author":"E Santamaria","year":"2018","unstructured":"Santamaria E, Izquierdo I, Valle M, Vermeulen J, Potter P. Rupatadine oral solution for 2\u20135-year-old children with allergic rhinitis: a safety, open-label, prospective study. J Asthma Allergy. 2018;11:225\u201331. https:\/\/doi.org\/10.2147\/JAA.S164632.","journal-title":"J Asthma Allergy"},{"issue":"Suppl 87","key":"614_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1398-9995.2008.01640.x","volume":"63","author":"J Mullol","year":"2008","unstructured":"Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(Suppl 87):5\u201328. https:\/\/doi.org\/10.1111\/j.1398-9995.2008.01640.x.","journal-title":"Allergy"},{"key":"614_CR50","unstructured":"Prescribing information of Allegra (fexofenadine hydrochloride capsules and tablets). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20872se8-003,20625se8-010_allegra_lbl.pdf."},{"key":"614_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/jaa.s3092","volume":"1","author":"D Axelrod","year":"2008","unstructured":"Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy. 2008;1:19\u201329. https:\/\/doi.org\/10.2147\/jaa.s3092.","journal-title":"J Asthma Allergy"},{"key":"614_CR52","unstructured":"Craun KL, Schury MP. 2020. Fexofenadine. StatPearls. Treasure Island (FL)."},{"issue":"6","key":"614_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0009-9236(98)90052-2","volume":"64","author":"T Russell","year":"1998","unstructured":"Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64(6):612\u201321. https:\/\/doi.org\/10.1016\/S0009-9236(98)90052-2.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"614_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/bdd.425","volume":"25","author":"R Krishna","year":"2004","unstructured":"Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos. 2004;25(9):373\u201387. https:\/\/doi.org\/10.1002\/bdd.425.","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"614_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/2229-5178.73262","volume":"1","author":"KV Godse","year":"2010","unstructured":"Godse KV, Nadkarni NJ, Jani G, Ghate S. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J. 2010;1(1):45\u20136. https:\/\/doi.org\/10.4103\/2229-5178.73262.","journal-title":"Indian Dermatol Online J"},{"key":"614_CR56","unstructured":"FDA: 2020 Fexofenadine. https:\/\/www.drugs.com\/pro\/fexofenadine.html (2020).Accessed."},{"issue":"2","key":"614_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1046\/j.1365-2125.1999.00993.x","volume":"48","author":"I Hindmarch","year":"1999","unstructured":"Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol. 1999;48(2):200\u20136. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00993.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"614_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119551","volume":"10","author":"E Poluzzi","year":"2015","unstructured":"Poluzzi E, Raschi E, Godman B, Koci A, Moretti U, Kalaba M, et al. Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe. PLoS ONE. 2015;10(3): e0119551. https:\/\/doi.org\/10.1371\/journal.pone.0119551.","journal-title":"PLoS ONE"},{"issue":"5","key":"614_CR59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/s0091-6749(99)70070-9","volume":"104","author":"PH Howarth","year":"1999","unstructured":"Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(5):927\u201333. https:\/\/doi.org\/10.1016\/s0091-6749(99)70070-9.","journal-title":"J Allergy Clin Immunol"},{"key":"614_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejphar.2015.08.016","volume":"765","author":"Y Hu","year":"2015","unstructured":"Hu Y, Sieck DE, Hsu WH. Why are second-generation H1-antihistamines minimally sedating? Eur J Pharmacol. 2015;765:100\u20136. https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.016.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"614_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11530910-000000000-00000","volume":"30","author":"M Ferrer","year":"2010","unstructured":"Ferrer M, Morais-Almeida M, Guizova M, Khanferyan R. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non-interventional, retrospective study. Clin Drug Investig. 2010;30(1):15\u201334. https:\/\/doi.org\/10.2165\/11530910-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"614_CR62","doi-asserted-by":"publisher","first-page":"S835","DOI":"10.1067\/mai.2003.1550","volume":"111","author":"TB Casale","year":"2003","unstructured":"Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111(5):S835\u201342. https:\/\/doi.org\/10.1067\/mai.2003.1550.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"614_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-016-0682-0","volume":"77","author":"K Snidvongs","year":"2017","unstructured":"Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W. Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Drugs. 2017;77(2):175\u201386. https:\/\/doi.org\/10.1007\/s40265-016-0682-0.","journal-title":"Drugs"},{"issue":"Suppl 3","key":"614_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1365-2222.1999.0290s3133.x","volume":"29","author":"I Hindmarch","year":"1999","unstructured":"Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy. 1999;29(Suppl 3):133\u201342. https:\/\/doi.org\/10.1046\/j.1365-2222.1999.0290s3133.x.","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"614_CR65","first-page":"127","volume":"18","author":"C Bunnag","year":"2000","unstructured":"Bunnag C, Jareoncharsri P, Tunsuriyawong P, Pumhirun P, Limprasertsiri S, Chochaipanichnon L, et al. A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis. Asian Pac J Allergy Immunol. 2000;18(3):127\u201333.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"614_CR66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2131\/jts.43.183","volume":"43","author":"K Ando","year":"2018","unstructured":"Ando K, Nakamura Y, Hagiwara-Nagasawa M, Harada H, Miyamoto H, Inamura N, et al. Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine. J Toxicol Sci. 2018;43(3):183\u201392. https:\/\/doi.org\/10.2131\/jts.43.183.","journal-title":"J Toxicol Sci"},{"issue":"3","key":"614_CR67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5114\/pdia.2014.43191","volume":"31","author":"A Olasinska-Wisniewska","year":"2014","unstructured":"Olasinska-Wisniewska A, Olasinski J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182\u20136. https:\/\/doi.org\/10.5114\/pdia.2014.43191.","journal-title":"Postepy Dermatol Alergol"},{"issue":"7201","key":"614_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bmj.319.7201.7a","volume":"319","author":"S Gottlieb","year":"1999","unstructured":"Gottlieb S. Antihistamine drug withdrawn by manufacturer. BMJ. 1999;319(7201):7. https:\/\/doi.org\/10.1136\/bmj.319.7201.7a.","journal-title":"BMJ."},{"issue":"451","key":"614_CR69","first-page":"148","volume":"50","author":"PM Craig-McFeely","year":"2000","unstructured":"Craig-McFeely PM, Freemantle SL, Pearce GL, Shakir SA. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Br J Gen Pract. 2000;50(451):148.","journal-title":"Br J Gen Pract"},{"issue":"9157","key":"614_CR70","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/s0140-6736(99)01009-0","volume":"353","author":"YM Pinto","year":"1999","unstructured":"Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet. 1999;353(9157):980. https:\/\/doi.org\/10.1016\/s0140-6736(99)01009-0.","journal-title":"Lancet"},{"issue":"6","key":"614_CR71","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1365-2222.2000.00914.x","volume":"30","author":"P Van Cauwenberge","year":"2000","unstructured":"Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30(6):891\u20139. https:\/\/doi.org\/10.1046\/j.1365-2222.2000.00914.x.","journal-title":"Clin Exp Allergy"},{"key":"614_CR72","unstructured":"FDA: 2018 Allergic rhinitis: developing drug products for treatment. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/allergic-rhinitis-developing-drug-products-treatment-guidance-industry (2018).Accessed."},{"issue":"3","key":"614_CR73","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaci.2010.06.047","volume":"126","author":"JL Brozek","year":"2010","unstructured":"Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466\u201376. https:\/\/doi.org\/10.1016\/j.jaci.2010.06.047.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"614_CR74","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/all.12372","volume":"69","author":"HJ Chong Neto","year":"2014","unstructured":"Chong Neto HJ, Rosario CS, Rosario BA, Chong FH, Grasselli EA, Silva FC, et al. Allergic rhinitis in preschool children from Southern Brazil. Allergy. 2014;69(4):545\u20137. https:\/\/doi.org\/10.1111\/all.12372.","journal-title":"Allergy"},{"issue":"4","key":"614_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jped.2013.01.001","volume":"89","author":"M Geraldini","year":"2013","unstructured":"Geraldini M, Chong Neto HJ, Riedi CA, Rosario NA. Epidemiology of ocular allergy and co-morbidities in adolescents. J Pediatr. 2013;89(4):354\u201360. https:\/\/doi.org\/10.1016\/j.jped.2013.01.001.","journal-title":"J Pediatr."},{"issue":"1","key":"614_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2500\/aap2008.29.3080","volume":"29","author":"CA Schad","year":"2008","unstructured":"Schad CA, Skoner DP. Antihistamines in the pediatric population: achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria. Allergy Asthma Proc. 2008;29(1):7\u201313. https:\/\/doi.org\/10.2500\/aap2008.29.3080.","journal-title":"Allergy Asthma Proc"},{"key":"614_CR77","unstructured":"Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. 2013 Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol. 23(3):141\u20134; (quiz 2 p preceding 5)."},{"issue":"4","key":"614_CR78","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jaip.2018.04.012","volume":"6","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier T, Bernstein JA. A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines. J Allergy Clin Immunol Pract. 2018;6(4):1144\u201351. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.012.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"614_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","volume":"7","author":"MT van den Elzen","year":"2017","unstructured":"van den Elzen MT, van Os-Medendorp H, van den Brink I, van den Hurk K, Kouznetsova OI, Lokin A, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:4. https:\/\/doi.org\/10.1186\/s13601-017-0141-3.","journal-title":"Clin Transl Allergy"},{"issue":"7","key":"614_CR80","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","volume":"73","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393\u2013414. https:\/\/doi.org\/10.1111\/all.13397.","journal-title":"Allergy"},{"issue":"4","key":"614_CR81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1081-1206(10)62671-3","volume":"83","author":"EO Meltzer","year":"1999","unstructured":"Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83(4):311\u20137. https:\/\/doi.org\/10.1016\/S1081-1206(10)62671-3.","journal-title":"Ann Allergy Asthma Immunol"}],"updated-by":[{"DOI":"10.1186\/s13223-022-00754-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000}}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00614-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T12:06:40Z","timestamp":1672142800000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00614-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00614-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13223-022-00754-3","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13223-022-00754-3","URL":"https:\/\/doi.org\/10.1186\/s13223-022-00754-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EOM is a speaker for, a member of an advisory board for ALK, GlaxoSmithKline, Glenmark, Merck, Mylan and Regeneron\/SanofiGenzyme, a consultant or advisory board member for AstraZeneca, Axdev, Boehringer Ingelheim, Church & Dwight, GossamerBio, Novartis and Principia. NAR is a speaker for Takeda, a speaker and a member of an advisory board for Sanofi, Boehringer Ingelheim, AstraZeneca, Chiesi and Mylan and reports research grants from Sanofi, Vertex, AstraZeneca and Janssen. HVB has no conflicts of interest to disclose. LL was an employee of Sanofi and may hold shares and\/or stock options in the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}